How low can we go?, page-87

I specifically mentioned that comparing to pred (or to HA control) was for the target market, not for FDA approval. So glad we agree on that point.

Reimbursement is different in the states, of course. Many people with CLBP will have insurance. But most people have insurance through their work, and many with CLBP are unable to work. Almost all insurance has massive deductibles as well (well in the thousands), so the point still stands.

All I'm saying is at this stage, even if they got FDA approval tomorrow, they would need to replicate these results with another robust study before they could expect people to shell out big bucks for this therapy (in any significant amount). Assuming an approval should all of a sudden justify a $45 price tag is outrageous ($30 billion company?).

Purely IMO.

Speculate all you want, though

What's lovely about this is we will know who is right eventually! And tbh id rather be wrong